View Older Stories View More Recent Stories

May 3, 2018 01:00AM Celyad Successfully Administers CYAD-01 in First Patients in SHRINK and LINK Trials
Apr 27, 2018 05:46AM Celyad SA (CYAD) Announces THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
Apr 27, 2018 02:30AM Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
Apr 27, 2018 02:30AM Haematologica publishes Celyad THINK Study Case Report of CYAD-01 Induced Complete Remission in Relapsed/Refractory AML Patient
Mar 29, 2018 01:00AM Celyad to Present Updates On CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018
Mar 29, 2018 01:00AM Celyad to Present Updates on CYAD-01 at the American Association for Cancer Research (AACR) Annual Meeting 2018
Mar 22, 2018 05:01PM Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018
Mar 22, 2018 04:01PM Celyad Reports 2017 Financial and Operating Results and Expected Key Milestones for 2018
Feb 13, 2018 01:00AM Celyad to Host Key Opinion Leader Meeting on CAR-T Therapy for the Treatment of Blood Cancers
Nov 21, 2017 04:30PM Celyad to Present at the 29th Annual Piper Jaffray Healthcare Conference
Nov 17, 2017 01:00AM Celyad Announces Third Quarter 2017 Business Update
Nov 17, 2017 01:00AM Celyad Announces Third Quarter 2017 Business Update
Oct 3, 2017 06:38AM Celyad SA (CYAD) Reports First Complete Response in Relapsed Refractory AML Patient in THINK Trial
Oct 3, 2017 01:00AM Celyad reports a first complete response in a relapsed refractory AML patient in the THINK trial
Oct 3, 2017 01:00AM Celyad Reports a First Complete Response in a Relapsed Refractory AML Patient in the THINK Trial
Sep 20, 2017 04:30PM Celyad to Present at the Cantor Fitzgerald Global Healthcare Conference
Aug 29, 2017 01:00AM Celyad Reports First Half 2017 Financial Results and Operational Progress
Aug 29, 2017 01:00AM Celyad Reports First Half 2017 Financial Results and Operational Progress
Aug 4, 2017 01:00AM Celyad announces new agreements with Celdara Medical and Dartmouth College
Aug 4, 2017 01:00AM Celyad announces new agreements with Celdara Medical and Dartmouth College
Jul 31, 2017 06:30AM BioLife Solutions Executes Supply Agreement with Celyad for CryoStor® Use in Natural Killer Receptor based T-Cell (NKR-T) Platform Targeting Solid Tumors and Blood Cancers
Jul 20, 2017 06:17AM Celyad SA (CYAD) Initiates SHRINK Trial With CYAD-01
Jul 20, 2017 01:00AM Celyad announces initiation of the SHRINK trial
Jul 20, 2017 01:00AM Celyad Announces Initiation of the SHRINK Trial
Jun 21, 2017 06:20AM Celyad SA (CYAD) Publishes Report with Additional Pre-clinical Data in Support of THINK trial
Jun 21, 2017 05:00AM Celyad publishes additional pre-clinical data in support of THINK trial
Jun 21, 2017 04:00AM Celyad publishes additional pre-clinical data in support of THINK trial
Jun 19, 2017 06:42AM Celyad SA (CYAD) Announces Early Results at First Dose Level of Solid Arm of THINK Trial
Jun 19, 2017 01:00AM Celyad reports promising early results at first dose level of the solid arm of the THINK trial
Jun 19, 2017 01:00AM Celyad Reports Promising Early Results at First Dose Level of the Solid Arm of the THINK Trial
Jun 12, 2017 04:00AM Celyad: Notice of Extraordinary General Meeting to be held on 29 June 2017
May 30, 2017 06:21AM Celyad SA (CYAD) Receives Additional US Patent for Cancer Treatment based on TCR-deficient CAR-T Cells
May 30, 2017 01:00AM Celyad obtains additional US patent for allogeneic cancer treatment based on TCR-deficient CAR-T cells
May 30, 2017 01:00AM Celyad obtains additional US patent for cancer treatment based on TCR-deficient allogeneic CAR-T cells
May 19, 2017 01:00AM Celyad Announces First Quarter 2017 Business Update
May 19, 2017 01:00AM Celyad Announces First Quarter 2017 Business Update
May 11, 2017 06:20AM Celyad SA (CYAD) Granted FDA Fast Track Status for C-Cure
May 11, 2017 01:00AM Celyad SA: Notice of Extraordinary General Meeting to be held on the 12 June 2017
May 11, 2017 01:00AM FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®
May 11, 2017 01:00AM FDA grants Fast Track Designation for Celyad’s ischemic heart failure therapy, C-Cure®
May 3, 2017 01:00AM Celyad to Present at the Deutsche Bank 42nd Annual Health Care Conference
May 2, 2017 06:26AM Celyad (CYAD), Novartis (NVS) Enter Non-Exclusive License for Allogeneic TCR-Deficient CAR-T Cells
May 2, 2017 02:00AM Celyad grants to Novartis a non-exclusive license for its allogeneic TCR-deficient CAR-T cells patents
May 2, 2017 01:00AM Celyad Grants to Novartis a Non-Exclusive License for Its Allogeneic TCR-Deficient CAR-T Cells Patents
Apr 28, 2017 02:00AM Celyad initiates second dose escalation in THINK trial in first US patient
Apr 28, 2017 01:00AM Celyad Initiates Second Dose Escalation in THINK Trial in First US Patient
Apr 4, 2017 05:59AM Celyad: Notice of Annual General Meeting to Be Held on the 5 May 2017
Mar 23, 2017 02:00AM Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017
Mar 23, 2017 02:00AM Celyad Reports 2016 Financial and Operating Results and Expected Key Milestones for 2017
Mar 16, 2017 06:33AM Celyad (CYAD) Says USPTO Rejects Reexamination Request Against Patent for Production of Allogeneic TCR-Deficient CAR-T Cells
View More Recent Stories View Older Stories